AIM ImmunoTech (AIM) Non Operating Income (2017 - 2021)
AIM ImmunoTech's (AIM) quarterly Non Operating Income came in at $51000.0 in Q2 2021, up 10.87% YoY from $46000.0 in Q2 2020, and down 29.17% on a QoQ basis from $72000.0 in Q1 2021.
AIM ImmunoTech (AIM) Non Operating Income (2017 - 2021) Analysis & Trends
AIM ImmunoTech (AIM) has 5 years of Non Operating Income data on file, last reported at $51000.0 in Q2 2021.
- Quarterly Non Operating Income rose 10.87% year-over-year to $51000.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $280000.0 (up 133.33% YoY) and the FY2020 annual result came in at $219000.0, up 146.07% from the prior year.
- Non Operating Income eased to $51000.0 in Q2 2021, from $72000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $88000.0 in Q4 2020 to a low of -$13000.0 in Q4 2018.
- A 5-year average of $31312.5 and a median of $24500.0 in 2017 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2018 — Non Operating Income tumbled 176.92% — and 2020, when it soared 762.5%.
- Tracing AIM's Non Operating Income over 5 years: stood at $28000.0 in 2017, then tumbled by 146.43% to -$13000.0 in 2018, then soared by 446.15% to $45000.0 in 2019, then jumped by 95.56% to $88000.0 in 2020, then plunged by 42.05% to $51000.0 in 2021.
- The last three Non Operating Income figures came in at $51000.0 (Q2 2021), $72000.0 (Q1 2021), and $88000.0 (Q4 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 51,000.00 |
| Mar 31, 2021 | 72,000.00 |
| Dec 31, 2020 | 88,000.00 |
| Sep 30, 2020 | 69,000.00 |
| Jun 30, 2020 | 46,000.00 |
| Mar 31, 2020 | 21,000.00 |
| Dec 31, 2019 | 45,000.00 |
| Sep 30, 2019 | 8,000.00 |
| Jun 30, 2019 | 16,000.00 |
| Mar 31, 2019 | 12,000.00 |
| Dec 31, 2018 | -13,000.00 |
| Sep 30, 2018 | -10,000.00 |
| Jun 30, 2018 | 51,000.00 |
| Mar 31, 2018 | 4,000.00 |
| Dec 31, 2017 | 28,000.00 |
| Sep 30, 2017 | 13,000.00 |